Related Experiment Video
Updated: Mar 19, 2026
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
Published on: August 29, 2017
Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a
Hsih-Te Yang1, Hong Yang2, Jung-Hsien Chiang3
1Institute of Medical Informatics, Department of Computer Science and Information Engineering, National Cheng Kung University, Taiwan; Institute of Oral Medicine, National Cheng Kung University College of Medicine, Taiwan.
Abstract:
Antibodies (Abs) are regarded as a newly emerging form of therapeutics that can provide passive protection against influenza. Although the application of genomics in clinics has increased dramatically, the number of therapeutics available for the treatment of many diseases remains insufficient. To translate genomics into medicines, we established a computational workflow to reconstruct 3D structures of hemagglutinin [HA, antigen (Ag)] and Ab for modeling Ab-HA interactions, based on their protein sequences. This platform was capable of testing the validity of bioinformatics predictions against viral neutralization titers for four Abs: CH65, CR8020, C05, and 5J8. By considering off-target effects, CR8020, the only successful candidate in clinical trials, was prospectively identified. Our approach could facilitate the discovery of Ab drugs against infectious diseases.
